JP2008521831A - Ｐｐａｒ活性化合物 - Google Patents

Ｐｐａｒ活性化合物 Download PDF

Info

Publication number
JP2008521831A
JP2008521831A JP2007543613A JP2007543613A JP2008521831A JP 2008521831 A JP2008521831 A JP 2008521831A JP 2007543613 A JP2007543613 A JP 2007543613A JP 2007543613 A JP2007543613 A JP 2007543613A JP 2008521831 A JP2008521831 A JP 2008521831A
Authority
JP
Japan
Prior art keywords
optionally substituted
disease
substituted lower
group
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521831A5 (enExample
Inventor
リン，ジャック
イブラヒム，プラバ，エヌ．
アーティス，ディーン，アール．
ジャン，チャオ
ワン，ウェイルー
シ，シェンフア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plexxikon Inc
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of JP2008521831A publication Critical patent/JP2008521831A/ja
Publication of JP2008521831A5 publication Critical patent/JP2008521831A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
JP2007543613A 2004-11-30 2005-11-29 Ｐｐａｒ活性化合物 Pending JP2008521831A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63189304P 2004-11-30 2004-11-30
US71525805P 2005-09-07 2005-09-07
PCT/US2005/043412 WO2006060535A2 (en) 2004-11-30 2005-11-29 Indole derivatives for use as ppar active compounds

Publications (2)

Publication Number Publication Date
JP2008521831A true JP2008521831A (ja) 2008-06-26
JP2008521831A5 JP2008521831A5 (enExample) 2009-01-22

Family

ID=36284449

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543613A Pending JP2008521831A (ja) 2004-11-30 2005-11-29 Ｐｐａｒ活性化合物

Country Status (6)

Country Link
US (1) US20060135540A1 (enExample)
EP (1) EP1833787A2 (enExample)
JP (1) JP2008521831A (enExample)
AU (1) AU2005311826A1 (enExample)
CA (1) CA2589896A1 (enExample)
WO (1) WO2006060535A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022537103A (ja) * 2019-06-17 2022-08-24 ウーツェーベー ファルマ ゲーエムベーハー 多発性硬化症のようなｃｎｓ障害を治療するためのｇｐｒ１７モジュレーターとしてのｎ‐（フェニル）‐インドール‐３‐スルホンアミド誘導体及び関連化合物

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) * 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
WO2007127791A2 (en) * 2006-04-25 2007-11-08 The Administrators Of The Tulane Educational Fund New pharmacological method for treatment of neuropathic pain
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008094860A2 (en) 2007-01-30 2008-08-07 Allergan, Inc. Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists
SI2124944T1 (sl) 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
GB0715048D0 (en) * 2007-08-02 2007-09-12 Glaxo Group Ltd Novel compounds
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP5502076B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規化合物
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
EP2501236B1 (en) 2009-11-18 2017-03-29 Plexxikon Inc. N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
CA2784393A1 (en) 2009-12-23 2011-06-30 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
KR20120117905A (ko) 2010-01-28 2012-10-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 프로테아좀 활성을 향상시키는 조성물 및 방법
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
TR201906779T4 (tr) 2011-05-12 2019-05-21 Proteostasis Therapeutics Inc Proteostaz regülatörleri.
CA2836474A1 (en) 2011-05-17 2012-11-22 Plexxikon Inc. Kinase modulation and indications therefor
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
CA2885259A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
ME03000B (me) 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
CN105073747B (zh) 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
RU2015149937A (ru) 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2774177T3 (es) 2014-09-15 2020-07-17 Plexxikon Inc Compuestos heterocíclicos y usos de estos
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
HK1255102A1 (zh) 2015-09-21 2019-08-02 Plexxikon Inc. 杂环化合物及其应用
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2017123826A1 (en) 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
US10160747B2 (en) 2016-03-16 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TW201819361A (zh) 2016-09-03 2018-06-01 印度商托仁特生技有限公司 新穎吲唑化合物
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
WO2018175311A1 (en) 2017-03-20 2018-09-27 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
BR112019028235B1 (pt) 2017-07-25 2024-04-30 Plexxikon, Inc. Composições e seus métodos de preparação
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
CN109678784A (zh) * 2017-10-19 2019-04-26 天津师范大学 硫醚化吲哚类化合物及其制备方法
CA3080197C (en) 2017-10-27 2023-12-19 Plexxikon Inc. Formulations of a compound modulating kinases
US11149011B2 (en) 2018-03-20 2021-10-19 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
AU2021263383A1 (en) 2020-04-29 2022-11-24 Plexxikon Inc. Synthesis of heterocyclic compounds

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
WO1995026955A1 (en) * 1994-03-30 1995-10-12 Zeria Pharmaceutical Co., Ltd. Indole derivative and medicine containing the same
WO2003064387A2 (en) * 2002-02-01 2003-08-07 F. Hoffman-La Roche Ag Substituted indoles as alpha-1 agonists
US6608059B1 (en) * 2000-06-27 2003-08-19 Smithkline Beecham Corporation Fatty acid synthase inhibitors
WO2004007451A1 (en) * 2002-07-17 2004-01-22 Astrazeneca Ab Indole-3-sulphur derivatives
WO2004020409A1 (en) * 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2005056522A2 (en) * 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
WO2005121141A1 (en) * 2004-06-10 2005-12-22 Oxagen Limited Pyrrolopyridine derivatives and use thereof for treating diseases mediated by prostaglandin d2 (pgd2)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
US5075313A (en) * 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
DE69932414T2 (de) * 1998-02-23 2007-02-22 South Alabama Medical Science Foundation, Mobile Indol-3-propionsäure, salze und ester davon als arzneimittel #
US6329389B1 (en) * 1998-04-08 2001-12-11 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
US6331537B1 (en) * 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
IL160845A0 (en) * 2001-09-14 2004-08-31 Tularik Inc Linked biaryl compounds
BRPI0412684A (pt) * 2003-07-17 2006-10-03 Plexxinko Inc compostos ppar-ativos
US7348338B2 (en) * 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
JP2007508363A (ja) * 2003-10-14 2007-04-05 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
WO1995026955A1 (en) * 1994-03-30 1995-10-12 Zeria Pharmaceutical Co., Ltd. Indole derivative and medicine containing the same
US6608059B1 (en) * 2000-06-27 2003-08-19 Smithkline Beecham Corporation Fatty acid synthase inhibitors
WO2003064387A2 (en) * 2002-02-01 2003-08-07 F. Hoffman-La Roche Ag Substituted indoles as alpha-1 agonists
WO2004007451A1 (en) * 2002-07-17 2004-01-22 Astrazeneca Ab Indole-3-sulphur derivatives
WO2004020409A1 (en) * 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2005056522A2 (en) * 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
WO2005121141A1 (en) * 2004-06-10 2005-12-22 Oxagen Limited Pyrrolopyridine derivatives and use thereof for treating diseases mediated by prostaglandin d2 (pgd2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022537103A (ja) * 2019-06-17 2022-08-24 ウーツェーベー ファルマ ゲーエムベーハー 多発性硬化症のようなｃｎｓ障害を治療するためのｇｐｒ１７モジュレーターとしてのｎ‐（フェニル）‐インドール‐３‐スルホンアミド誘導体及び関連化合物
JP7631235B2 (ja) 2019-06-17 2025-02-18 ウーツェーベー ファルマ ゲーエムベーハー 多発性硬化症のようなｃｎｓ障害を治療するためのｇｐｒ１７モジュレーターとしてのｎ‐（フェニル）‐インドール‐３‐スルホンアミド誘導体及び関連化合物
US12358875B2 (en) 2019-06-17 2025-07-15 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis

Also Published As

Publication number Publication date
US20060135540A1 (en) 2006-06-22
AU2005311826A1 (en) 2006-06-08
CA2589896A1 (en) 2006-06-08
EP1833787A2 (en) 2007-09-19
WO2006060535A2 (en) 2006-06-08
WO2006060535A3 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
JP2008521829A (ja) Ｐｐａｒ活性化合物
CA2589896A1 (en) Indole derivatives for use as ppar active compounds
US20070072904A1 (en) PPAR active compounds
JP2009509932A (ja) Ｐｐａｒ活性化合物
JP2009507846A (ja) Ｐｐａｒ活性化合物
Boubia et al. Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) α/γ/δ triple activators: discovery of lanifibranor, a new antifibrotic clinical candidate
US8053463B2 (en) PPAR active compounds
JP4598278B2 (ja) Ｐｐａｒ受容体リガンドとしてのジアリール酸誘導体
KR100762762B1 (ko) Ｐｐａｒ의 조절인자로서의 아릴 화합물 및 신진대사장애의 치료 방법
WO2014207213A1 (en) Novel inhibitors of protein kinase c epsilon signaling
WO2000023442A1 (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
US20070208026A1 (en) N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders
US20070117860A1 (en) Bicyclic indolinesulphonamide derivatives
WO2020051707A1 (en) Indole-oxadiazole compounds and their therapeutic use
US20240391928A1 (en) Compositions for the treatment of food and chemical addiction and methods of making and using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120731